{"title":"用于临床的 6-溴-7-[11C]甲基嘌呤的改进合成。","authors":"Toshimitsu Okamura, Tatsuya Kikuchi, Masanao Ogawa, Ming-Rong Zhang","doi":"10.1186/s41181-024-00240-8","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Multidrug resistance-associated protein 1 (MRP1), an energy-dependent efflux pump, is expressed widely in various tissues and contributes to many physiological and pathophysiological processes. 6-Bromo-7-[<sup>11</sup>C]methylpurine ([<sup>11</sup>C]7m6BP) is expected to be useful for the assessment of MRP1 activity in the human brain and lungs. However, the radiochemical yield (RCY) in the synthesis of [<sup>11</sup>C]7m6BP was low, limiting its clinical application, because the methylation of the precursor with [<sup>11</sup>C]CH<sub>3</sub>I provided primarily the undesired isomer, 6-bromo-9-[<sup>11</sup>C]methylpurine ([<sup>11</sup>C]9m6BP). To increase the RCY of [<sup>11</sup>C]7m6BP, we investigated conditions for improving the [<sup>11</sup>C]7m6BP/[<sup>11</sup>C]9m6BP selectivity of the methylation reaction.</p><h3>Results</h3><p>[<sup>11</sup>C]7m6BP was manually synthesized via the methylation of 6-bromopurine with [<sup>11</sup>C]CH<sub>3</sub>I in various solvents and at different temperatures in the presence of potassium carbonate for 5 min. Several less polar solvents, including tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), and ethyl acetate (AcOEt) improved the [<sup>11</sup>C]7m6BP/[<sup>11</sup>C]9m6BP selectivity from 1:1 to 2:1, compared with the conventionally used solvents for the alkylation of 6-halopurines, acetone, acetonitrile, and <i>N</i>,<i>N</i>-dimethylformamide. However, a higher temperature (140 °C or 180 °C) was needed to progress the <sup>11</sup>C-methylation in the less polar solvents, and the manual conditions could not be directly translated to an automated synthesis. [<sup>11</sup>C]Methyl triflate ([<sup>11</sup>C]CH<sub>3</sub>OTf) was thus used as a methylating agent to increase the conversion at a lower temperature. The <sup>11</sup>C-methylation using [<sup>11</sup>C]CH<sub>3</sub>OTf at 100 °C proceeded efficiently in THF, 2-MeTHF, and AcOEt with maintenance of the improved selectivity. Starting from 28 to 34 GBq [<sup>11</sup>C]CO<sub>2</sub>, [<sup>11</sup>C]7m6BP was produced with 2.3–2.6 GBq for THF, 2.7–3.3 GBq for AcOEt, and 2.8–3.9 GBq for 2-MeTHF at approximately 30 min after the end of bombardment (<i>n</i> = 3 per solvent). The isolated RCYs (decay corrected) for THF, 2-MeTHF, and AcOEt were 24–28%, 29–35%, and 22–31% (<i>n</i> = 3), respectively.</p><h3>Conclusions</h3><p>The use of THF, 2-MeTHF, and AcOEt improved the [<sup>11</sup>C]7m6BP/[<sup>11</sup>C]9m6BP selectivity in the methylation reaction, and the improved method provided [<sup>11</sup>C]7m6BP with sufficient radioactivity for clinical use.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"9 1","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00240-8","citationCount":"0","resultStr":"{\"title\":\"Improved synthesis of 6-bromo-7-[11C]methylpurine for clinical use\",\"authors\":\"Toshimitsu Okamura, Tatsuya Kikuchi, Masanao Ogawa, Ming-Rong Zhang\",\"doi\":\"10.1186/s41181-024-00240-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Multidrug resistance-associated protein 1 (MRP1), an energy-dependent efflux pump, is expressed widely in various tissues and contributes to many physiological and pathophysiological processes. 6-Bromo-7-[<sup>11</sup>C]methylpurine ([<sup>11</sup>C]7m6BP) is expected to be useful for the assessment of MRP1 activity in the human brain and lungs. However, the radiochemical yield (RCY) in the synthesis of [<sup>11</sup>C]7m6BP was low, limiting its clinical application, because the methylation of the precursor with [<sup>11</sup>C]CH<sub>3</sub>I provided primarily the undesired isomer, 6-bromo-9-[<sup>11</sup>C]methylpurine ([<sup>11</sup>C]9m6BP). To increase the RCY of [<sup>11</sup>C]7m6BP, we investigated conditions for improving the [<sup>11</sup>C]7m6BP/[<sup>11</sup>C]9m6BP selectivity of the methylation reaction.</p><h3>Results</h3><p>[<sup>11</sup>C]7m6BP was manually synthesized via the methylation of 6-bromopurine with [<sup>11</sup>C]CH<sub>3</sub>I in various solvents and at different temperatures in the presence of potassium carbonate for 5 min. Several less polar solvents, including tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), and ethyl acetate (AcOEt) improved the [<sup>11</sup>C]7m6BP/[<sup>11</sup>C]9m6BP selectivity from 1:1 to 2:1, compared with the conventionally used solvents for the alkylation of 6-halopurines, acetone, acetonitrile, and <i>N</i>,<i>N</i>-dimethylformamide. However, a higher temperature (140 °C or 180 °C) was needed to progress the <sup>11</sup>C-methylation in the less polar solvents, and the manual conditions could not be directly translated to an automated synthesis. [<sup>11</sup>C]Methyl triflate ([<sup>11</sup>C]CH<sub>3</sub>OTf) was thus used as a methylating agent to increase the conversion at a lower temperature. The <sup>11</sup>C-methylation using [<sup>11</sup>C]CH<sub>3</sub>OTf at 100 °C proceeded efficiently in THF, 2-MeTHF, and AcOEt with maintenance of the improved selectivity. Starting from 28 to 34 GBq [<sup>11</sup>C]CO<sub>2</sub>, [<sup>11</sup>C]7m6BP was produced with 2.3–2.6 GBq for THF, 2.7–3.3 GBq for AcOEt, and 2.8–3.9 GBq for 2-MeTHF at approximately 30 min after the end of bombardment (<i>n</i> = 3 per solvent). The isolated RCYs (decay corrected) for THF, 2-MeTHF, and AcOEt were 24–28%, 29–35%, and 22–31% (<i>n</i> = 3), respectively.</p><h3>Conclusions</h3><p>The use of THF, 2-MeTHF, and AcOEt improved the [<sup>11</sup>C]7m6BP/[<sup>11</sup>C]9m6BP selectivity in the methylation reaction, and the improved method provided [<sup>11</sup>C]7m6BP with sufficient radioactivity for clinical use.</p></div>\",\"PeriodicalId\":534,\"journal\":{\"name\":\"EJNMMI Radiopharmacy and Chemistry\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-02-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-024-00240-8\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Radiopharmacy and Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s41181-024-00240-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-024-00240-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
Improved synthesis of 6-bromo-7-[11C]methylpurine for clinical use
Background
Multidrug resistance-associated protein 1 (MRP1), an energy-dependent efflux pump, is expressed widely in various tissues and contributes to many physiological and pathophysiological processes. 6-Bromo-7-[11C]methylpurine ([11C]7m6BP) is expected to be useful for the assessment of MRP1 activity in the human brain and lungs. However, the radiochemical yield (RCY) in the synthesis of [11C]7m6BP was low, limiting its clinical application, because the methylation of the precursor with [11C]CH3I provided primarily the undesired isomer, 6-bromo-9-[11C]methylpurine ([11C]9m6BP). To increase the RCY of [11C]7m6BP, we investigated conditions for improving the [11C]7m6BP/[11C]9m6BP selectivity of the methylation reaction.
Results
[11C]7m6BP was manually synthesized via the methylation of 6-bromopurine with [11C]CH3I in various solvents and at different temperatures in the presence of potassium carbonate for 5 min. Several less polar solvents, including tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), and ethyl acetate (AcOEt) improved the [11C]7m6BP/[11C]9m6BP selectivity from 1:1 to 2:1, compared with the conventionally used solvents for the alkylation of 6-halopurines, acetone, acetonitrile, and N,N-dimethylformamide. However, a higher temperature (140 °C or 180 °C) was needed to progress the 11C-methylation in the less polar solvents, and the manual conditions could not be directly translated to an automated synthesis. [11C]Methyl triflate ([11C]CH3OTf) was thus used as a methylating agent to increase the conversion at a lower temperature. The 11C-methylation using [11C]CH3OTf at 100 °C proceeded efficiently in THF, 2-MeTHF, and AcOEt with maintenance of the improved selectivity. Starting from 28 to 34 GBq [11C]CO2, [11C]7m6BP was produced with 2.3–2.6 GBq for THF, 2.7–3.3 GBq for AcOEt, and 2.8–3.9 GBq for 2-MeTHF at approximately 30 min after the end of bombardment (n = 3 per solvent). The isolated RCYs (decay corrected) for THF, 2-MeTHF, and AcOEt were 24–28%, 29–35%, and 22–31% (n = 3), respectively.
Conclusions
The use of THF, 2-MeTHF, and AcOEt improved the [11C]7m6BP/[11C]9m6BP selectivity in the methylation reaction, and the improved method provided [11C]7m6BP with sufficient radioactivity for clinical use.